Fabien C.
- Country
- Belgium
- Department
- Cardiology
Research Overview
- Evaluation of the Efficacy and Safety of BI 690517 and Empagliflozin in Patients with Symptomatic Heart Failure and LVEF ≥40%: A Phase III Randomized Controlled Trial
- Evaluation of Vicadrostat (BI 690517) and Empagliflozin Efficacy and Safety in Patients with Symptomatic Chronic Heart Failure and Reduced Ejection Fraction
Data & Insights
Has run more than one trial at 115 of 250 partner sites.
Specializations
Cardiovascular Medicine
This investigator specializes in the management and treatment of heart failure, with particular emphasis on innovative therapeutic approaches for various cardiac conditions.
- Heart Failure Management
- Reduced Ejection Fraction Treatment
- Cardiopulmonary Congestion
The investigator's work encompasses evaluation of novel therapeutic combinations and targeted treatments for cardiac dysfunction, focusing on improving outcomes in patients with compromised heart function.
Therapeutic Innovation
The investigator explores combination therapy approaches in cardiovascular medicine, particularly investigating the synergistic effects of multiple therapeutic agents.
- Combined Treatment Strategies
- Novel Therapeutic Agents
- Clinical Efficacy Assessment
Their research interests include evaluating innovative pharmaceutical interventions for heart failure management, with a focus on improving cardiovascular outcomes.
Clinical Outcomes
The investigator focuses on measuring and improving key clinical outcomes in cardiovascular patients, particularly those with compromised cardiac function.
- Cardiovascular Mortality
- Heart Failure Hospitalization
- Cardiac Function Assessment
Their work involves evaluation of therapeutic interventions targeting improved survival and reduced hospitalization rates in heart failure patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.